Trevi Therapeutics (TRVI) Total Liabilities (2018 - 2026)

Trevi Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $7.5 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 0.9% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $7.5 million (down 0.9% YoY), while the FY2025 annual figure was $10.2 million, down 9.43% from the prior year.
• Total Liabilities for Q1 2026 stood at $7.5 million, down from $10.2 million in the prior quarter.
• The five-year high for Total Liabilities was $20.9 million in Q2 2022, with the low at $5.9 million in Q2 2023.
• The 5-year median for Total Liabilities is $9.8 million (2025), against an average of $11.1 million.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities sank 71.75% in 2023, then soared 64.18% in 2024.
• Trevi Therapeutics' Total Liabilities stood at $15.6 million in 2022, then slumped by 55.93% to $6.9 million in 2023, then jumped by 64.18% to $11.3 million in 2024, then declined by 9.43% to $10.2 million in 2025, then slipped by 26.64% to $7.5 million in 2026.
• Business Quant data shows TRVI's Total Liabilities at $7.5 million in Q1 2026, $10.2 million in Q4 2025, and $9.6 million in Q3 2025.